Lance Berberian
Known title: DirectorCIK: 0001102900
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Labcorp to Acquire OPKO Health's BioReference Assets for $722M. Labcorp has agreed to acquire select assets from OPKO Health's BioReference division for $722 million. This move expands Labcorp's capabilities in the diagnostics sector, a key area for the company's growth. The stock is currently trading near its 52-week high, reflecting investor interest in this strategic acquisition.
Transaction History
| PRVA | ▲ Buy | Grant | 8,463 | $0 | 5/20/2026 | View on chart |
| PRVA | ▲ Buy | Grant | 7,668 | $0 | 7/15/2025 | View on chart |
| LH | ▲ Buy | Grant | 3,325 | $0 | 3/27/2025 | View on chart |
| LH | ▼ Sell | Tax Withholding | 1,353 | $313K | 3/27/2025 | View on chart |
| LH | ▲ Buy | Option Exercise | 323 | — | 2/11/2025 | View on chart |
| LH | ▼ Sell | Tax Withholding | 86 | $21K | 2/11/2025 | View on chart |
| LH | ▲ Buy | Option Exercise | 354 | — | 2/7/2025 | View on chart |
| LH | ▼ Sell | Tax Withholding | 94 | $23K | 2/7/2025 | View on chart |
| LH | ▲ Buy | Option Exercise | 356 | — | 2/6/2025 | View on chart |
| LH | ▼ Sell | Tax Withholding | 94 | $23K | 2/6/2025 | View on chart |
| LH | ▼ Sell | Open Market | 2,245 | $516K | 8/5/2024 | View on chart |
| LH | ▼ Sell | Open Market | 9,848 | $2.3M | 8/5/2024 | View on chart |
| LH | ▼ Sell | Tax Withholding | 3,299 | $714K | 3/27/2024 | View on chart |
| LH | ▲ Buy | Option Exercise | 7,697 | — | 3/27/2024 | View on chart |
| LH | ▼ Sell | Tax Withholding | 87 | $20K | 2/12/2024 | View on chart |
| LH | ▲ Buy | Option Exercise | 324 | — | 2/11/2024 | View on chart |
| LH | ▼ Sell | Tax Withholding | 94 | $21K | 2/7/2024 | View on chart |
| LH | ▲ Buy | Option Exercise | 353 | — | 2/7/2024 | View on chart |
| LH | ▲ Buy | Option Exercise | 331 | — | 2/2/2024 | View on chart |
| LH | ▼ Sell | Tax Withholding | 89 | $20K | 2/2/2024 | View on chart |
| LH | ▼ Sell | Tax Withholding | 1,799 | $404K | 3/30/2023 | View on chart |
| LH | ▲ Buy | Grant | 4,509 | $0 | 3/30/2023 | View on chart |
| LH | ▼ Sell | Tax Withholding | 85 | $21K | 2/13/2023 | View on chart |
| LH | ▲ Buy | Option Exercise | 290 | — | 2/11/2023 | View on chart |
| LH | ▼ Sell | Tax Withholding | 108 | $26K | 2/6/2023 | View on chart |
| LH | ▲ Buy | Option Exercise | 374 | — | 2/4/2023 | View on chart |
| LH | ▼ Sell | Tax Withholding | 102 | $26K | 2/2/2023 | View on chart |
| LH | ▲ Buy | Option Exercise | 297 | — | 2/2/2023 | View on chart |
| LH | ▼ Sell | Tax Withholding | 2,360 | $652K | 3/28/2022 | View on chart |
| LH | ▲ Buy | Grant | 5,310 | $0 | 3/27/2022 | View on chart |
| LH | ▼ Sell | Tax Withholding | 694 | $189K | 2/14/2022 | View on chart |
| LH | ▼ Sell | Tax Withholding | 105 | $29K | 2/14/2022 | View on chart |
| LH | ▲ Buy | Option Exercise | 2,354 | — | 2/12/2022 | View on chart |
| LH | ▲ Buy | Option Exercise | 354 | — | 2/12/2022 | View on chart |
| LH | ▲ Buy | Option Exercise | 373 | — | 2/4/2022 | View on chart |
| LH | ▼ Sell | Tax Withholding | 109 | $30K | 2/4/2022 | View on chart |
| LH | ▲ Buy | Option Exercise | 296 | — | 2/2/2022 | View on chart |
| LH | ▼ Sell | Tax Withholding | 103 | $28K | 2/2/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 11, 2026
Privia Health to Report Q3 2026 Results on Nov 5
Privia Health Group is scheduled to announce its third-quarter 2026 financial results on November 5. Recent coverage highlights the company's role in healthcare automation aimed at reducing administrative costs. With the stock currently trading near its support level, investors will be watching the earnings report for updates on revenue trends and cost management.
Privia Health to Report Q3 2026 Results on Nov 5. Privia Health Group is scheduled to announce its third-quarter 2026 financial results on November 5. Recent coverage highlights the company's role in healthcare automation aimed at reducing administrative costs. With the stock currently trading near its support level, investors will be watching the earnings report for updates on revenue trends and cost management.